To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m 2 /day, days 1-3; cytarabine (AraC) 200 mg/m 2 /day, days 1-7; cladribine (2-CdA) 5 mg/m 2 /day, days 1-5, 400 untreated adult acute myeloid leukemia patients (including 63 with preceding myelodysplastic syndrome), aged 45 (16-60) years were randomized to either DAC-7 (n ¼ 200) or DA-7 (without 2-CdA, n ¼ 200). The overall CR rate equaled 72% for DAC-7 and 69% for DA-7 arm (P ¼ NS). After a single course of DAC-7 induction, the CR rate equaled 64% and was significantly higher compared to 47% in the DA-7 arm (P ¼ 0.0009). Median hospitalization time during the induction was 7 days shorter for DAC-7 compared to the DA-7 group (33 vs 40 days, P ¼ 0.002). Toxicity was comparable in both groups. The probability of 3-year leukemia-free survival (LFS) for DAC-7 and DA-7 group equaled 43 and 34%, respectively (P ¼ NS). There was a trend toward higher LFS rate for patients aged 440 years receiving DAC-7 compared with DA-7 regimen (44 vs 28%, P ¼ 0.05). This study proves that addition of 2-CdA increases antileukemic potency of DNR þ AraC regimen, thus resulting in a higher CR rate after one induction cycle when compared to DA-7, without additional toxicity. It shortens hospitalization time and may improve long-term survival in patients aged 440 years.
Introduction
In adult acute myeloid leukemia (AML), complete remission (CR) may be achieved in approximately 60-80% of patients aged less than 60 years. 1, 2 These results have been obtained since the introduction of the induction regimen containing 3 days of daunorubicin (DNR) and 7 days of cytarabine (AraC) 20 years ago by the Cancer and Leukemia Group B (CALGB). 3 Since that time a number of trials have prospectively compared DNR with another anthracycline (idarubicin) or anthracenedione (mitoxantrone). [4] [5] [6] [7] The addition of a third drug (thioguanine, etoposide) was an alternative attempt. 2, 8 Although some studies suggested that these modifications, resulting in treatment intensification, could improve CR rate, no clear advantage was demonstrated compared with DNR/AraC regimen, the latter still being considered a standard induction therapy for adult AML.
Another possible attempt to intensify induction treatment is the addition of a purine analogue like fludarabine (FA) or cladribine (2-CdA). 9 These drugs were demonstrated to increase cellular uptake of AraC and the accumulation of AraCTP in circulating blasts from patients with AML by 50-65%.
9-12 2-CdA-like FA was also shown to have a direct antileukemic activity resulting from the incorporation of its metabolites into the DNA of proliferating cells. 13 The synergistic effect of FA or 2-CdA with AraC has been studied in refractory or relapsed AML, resulting in CR rate of about 50% in this group of poor prognosis patients. [14] [15] [16] However, in a retrospective analysis of newly diagnosed AML, the FA þ AraC regimen had no advantage over idarubicin þ AraC. 17 A combination of 2-CdA, AraC and anthracycline was tested in a study on untreated, elderly AML patients showing no additional toxicity (Juliusson et al. Blood 2001; 98; abstract 123a). In 1999, Polish Adult Leukemia Group (PALG) conducted a phase II study on DNR þ AraC þ 2-CdA (DAC-7) as an induction therapy of previously untreated AML patients aged below 60 years. 18 Among 50 cases, the CR rate was 72% with almost all patients achieving remission after a single course of induction treatment. Those promising results together with an acceptable toxicity of the DAC-7 regimen stimulated us to investigate the comparison of this treatment modality with a standard DNR þ AraC (DA-7) regimen in a randomized, multicenter trial.
Patients and methods

Study population
In all, 400 patients with newly diagnosed AML entered the study in 15 Polish hematological centers belonging to PALG between May 1999 and June 2002. Patients were considered eligible if they fulfilled the following criteria: AML diagnosis established according to French-American-British (FAB) criteria, 19 immune phenotyping performed, age 16-60 years, informed consent obtained, and blood sample collected for cytogenetics and molecular biology. The exclusion criteria were: FAB M3 subtype with PML/RAR-alfa rearrangement and/or t(15;17), poor performance status (Karnofsky index o40%), preceding chemo-or radiotherapy for any reason, severe organ impairment and pregnancy. Patients with preceding myelodysplastic syndrome (MDS) were eligible for this study.
After obtaining informed written consent, patients were reported to the coordinating center, centrally stratified according to FAB subtype, age (o40 years and X40 years; this cutpoint was expected to divide the study population into approximately equal subgroups) and centers, and then randomly assigned to DAC-7 (n ¼ 200) arm or DA-7 (n ¼ 200) arm.
Karyotypes were interpreted using International System for Cytogenetic Nomenclature (1995) criteria. 20 Studies were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 mitotic cells examined. After receiving results of the cytogenetics and molecular biology, patients were further grouped including favorable, intermediate and unfavorable karyotype features according to the Southwest Oncology Group (SWOG) criteria. 21 The protocol was consistent with GMP principles and approved by local ethic committees in each participating center.
Treatment regimen
Patients randomized to the DAC-7 arm received the induction treatment consisting of DNR 60 mg/m 2 i.v. on days 1-3, AraC 200 mg/m 2 c.i. on days 1-7 and 2-CdA (Biodribin, Bioton, Poland) 5 mg/m 2 on days 1-5, whereas the comparative DA-7 treatment consisted of DNR and AraC in the same schedule without 2-CdA. Patients achieving CR entered consolidation therapy. In patients with partial remission (PR), the same induction regimen was repeated. In case of nonremission (NR) after the first course of induction therapy or PR/NR after two courses of induction treatment, patients were given CLAG (2-CdA 5 mg/m 2 i.v. on days 1-5; AraC 2 g/m 2 i.v. on days 1-5; granulocyte-colony stimulating factor (G-CSF) 5 mg/kg on days 0-5) as a second-line treatment regardless of the randomization arm. If CR was not obtained after CLAG, the patients were excluded from further study and entered alternative regimens (Figure 1) .
Consolidation treatment consisted of two consecutive courses: (1) 
Criteria for response
The patients were considered to be in CR if they fulfilled the following criteria: all neutrophil count (ANC) X1.8 Â 10 9 /l, PLT X100 Â 10 9 /l, blasts in bone marrow o5%, no blasts in peripheral blood and no extramedullary disease; hemoglobin level (Hb) X6.8 mmol/l was recommended before the start of consolidation. PR was established with bone marrow blasts 5-25% and peripheral blood blasts o5% with ANC 41.0 Â 10 9 /l, platelets (PLTs) 450 Â 10 9 /l, lymphoid nodes o2 cm, splenomegaly o2 cm below left costal arch, hepatomegaly o5 cm below right costal arch with considerable improvement of performance status. NR was established for patients who did not fulfill the above criteria. Early mortality (EM) was defined as death following induction treatment before it was possible to assess the remission status.
Bone marrow aspirate was performed after the first course of induction therapy as soon as the patient achieved peripheral blood morphology values required for CR, but not later than on day 50 since the start of the treatment. It was performed earlier if blasts persisted or reappeared in peripheral blood or no recovery was noticed until day 40.
The above criteria for response were based on earlier protocols and used in previous phase III studies by the PALG. 22 The remission status was assessed after completion of each course of induction treatment, after the end of consolidation, before every two maintenance courses and every 3 months after the end of maintenance, or after HSCT, unless earlier bone marrow examinations were indicated by peripheral blood changes inconsistent with CR.
Statistical methods
The primary end point was CR rate achieved after one course of induction therapy. The size of the study was based on power calculation. The type I error was fixed at a ¼ 0.05. With the power of 0.85, the target number of 400 patients was established to detect the 15% difference in CR rate obtained after one induction course (the expected difference was based on previous phase II study. 18 The overall CR rate after two or more induction regimens, the assessments of hematological and nonhematological toxicity as well as the rates of overall survival (OS) and leukemia-free survival (LFS) were secondary end points. Toxicity was assessed according to the WHO criteria. OS was defined as the time from the start of the treatment to death due to any cause and LFS was the time interval from the date of achieving CR to the first event of either a relapse or death in CR, whichever occurred first.
For the comparison of CR rates and incidence of adverse events between both randomization arms, w 2 -test was used. The duration of cytopenia as well as minimal neutrophil (ANC), lymphocyte (Lym) and PLT counts were compared using MannWhitney U-test.
The probabilities of recovery of ANC 40.5 Â 10 9 /l and PLT 450 Â 10 9 /l were calculated as cumulative incidence, whereas the OS and LFS rates were estimated using the Kaplan-Meier method. 23, 24 Both study groups were compared with respect to these parameters using the log-rank test.
Results
Patient characteristics
A total of 400 patients, 206 male and 194 female, with the median age of 45 (range 16-60) years, were enrolled in the study. All included patients were given induction treatment. No withdrawals were reported.
Karyotype was established in 246 cases (62%), with 43 (17%) patients having favorable cytogenetic features, 157 (64%) having intermediate cytogenetic features and 46 (19%) patients having unfavorable cytogenetic features. In 57 (14%) cases, the diagnosis of AML was preceded by MDS.
A total of 200 patients were randomized to the DAC-7 and 200 patients were assigned to the DA-7 arm. The cohorts were well balanced in terms of clinical and biological features. Detailed characteristics are listed in Table 1 .
Early clinical outcome
A single course of DAC-7 induction resulted in a significantly higher CR rate when compared with DA-7 therapy: 63.5 vs 47%, P ¼ 0.0009 n ( n CR rates were the same when NCI criteria, Patients with PR or NR after the first course of induction received another one or two lines of induction therapy. This led to achieving CR in an additional 8% of patients in the DAC-7 arm and 22% of patients in the DA-7 arm. Thus, the overall CR rate for the study groups equaled 72 and 69%, respectively (P ¼ NS) ( Table 2) .
For patients who achieved CR after a single induction course, the median time from the start of the treatment to the evaluation of the remission status equaled 40 (range 18-50) days for DAC-7 arm and 37 (range 20-50) days for the DA-7 group (P ¼ NS), whereas the interval between the start of induction and start of consolidation was 48 (range 27-84 days) and 45 (range 25-98) days, respectively (P ¼ NS). For those who achieved PR or NR status after the first induction treatment, the median time from the start of induction to the assessment of the remission status was 44 (range 18-50) days for DAC-7 and 41.5 (range 20-50) days for DA-7 (P ¼ NS), whereas the interval between the start of the first and the second induction course was 45 (range 19-51 days) and 42.5 (range 21-51) days, respectively (P ¼ NS).
The impact of different risk factors on CR rate was studied in cohorts of patients assorted according to various criteria. Concerning both groups under study, the overall CR rate was higher for patients with favorable cytogenetic features (81.5%) compared to the intermediate cytogenetic group (73%) and the unfavorable cytogenetic group (59%). Patients without cytogenetics (n ¼ 55) and with karyotype analysis failure (n ¼ 119) had CR rates of 67 and 58%, respectively. However, analysis of corresponding subgroups stratified according to the cytogenetic risk as well as the FAB subtype did not show significant differences between both study arms. It is to be stressed that significantly higher CR rate was achieved for patients with initial white blood cell count (WBC) 4100 Â 10 9 /l receiving DAC-7 treatment in comparison with DA-7 therapy (71 vs 43%, P ¼ 0.03). The difference was even more pronounced if only the first induction course is taken into account (61 vs 25%, respectively, P ¼ 0.008). Detailed data are listed in Table 3 .
Toxicity
All the patients experienced severe granulocytopenia and thrombocytopenia. Both study groups did not differ in terms of minimal PLT counts as well as ANC and PLT recovery. However, granulocytopenia and lymphopenia were significantly more profound after DAC-7 treatment compared with DA-7 therapy with the median minimal ANC equaling 0 (range 0-0.2) Â 10 9 /l vs 0 (range 0-0.5) Â 10 9 /l (P ¼ 0.05) and the median minimal Lym equaling 0.2 (range 0-0.9) Â 10 9 /l vs 0.3 (range 0-1.0) Â 10 9 /l (P ¼ 0.000002), respectively. Severe (grades III-IV) infections occurred in 39% of patients in the DAC-7 arm (etiology: bacterial -37%, fungal -8%, mixed -5%, negative culture -50%) and 34% of patients in the DA-7 arm (etiology: bacterial -43%, fungal -10%, mixed -8%, negative culture -39%) (P ¼ NS). In a group of patients without established etiology (n ¼ 64), infection was manifested as pneumonia (n ¼ 28 (75%) in DAC-7 and n ¼ 22 (82%) in DA-7 arm) and generalized septic symptoms (n ¼ 9 (25%) and n ¼ 5 (18%), respectively). Other nonhematological toxicities were infrequent and comparable for both study groups.
In all, 31 (15.5%) patients died of treatment-related complications in the DAC-7 arm compared to 28 (14%) patients in the DA-7 arm. Septic infections (n ¼ 17 (55%) for DAC-7 arm and n ¼ 13 (46%) in DA-7) and cerebral bleedings (n ¼ 12 (39%) and n ¼ 6 (20%), respectively) were the major causes of EM in both study groups. Since the death rate, as well as the frequency of severe infectious complications, where similar in both study arms, these events were related to an advanced status of the disease rather than treatment.
Details on hematological and nonhematological toxicity during induction treatment are listed in Table 4 .
No difference with regard to toxicity was found between both study arms during consolidation therapy.
Supportive therapy
Patients assigned to the DAC-7 arm stayed in the hospital 7 days shorter during induction phase of the treatment compared with those assigned to the DA-7 arm; median 33 (range 20-111) days vs 40 (15-90) days, P ¼ 0.002. This resulted from the higher percentage of patients receiving two or more courses of induction therapy in the DA-7 arm compared with the DAC-7 arm. The number of red blood cell concentrates and PLT transfusions as well as the duration of i.v. antibiotic therapy was comparable in both study groups. Only 7% of patients in the DAC-7 arm and 3.5% of patients in DA-7 arm were given G-CSF to stimulate ANC recovery after induction treatment ( Table 5 ).
The intensity of supportive treatment during consolidation did not differ for both study groups.
Postremission therapy and long-term outcome
Among patients who achieved CR, 84% completed both courses of consolidation in the DAC-7 arm and 81% in the DA-7 arm. The proportion of patients undergoing auto-HSCT and allo-HSCT in the DAC-7 group was 21.5 and 12.5%, whereas in the DA-7 group -23 and 14%, respectively. With the median follow-up of 1.5 years, the probability of OS at 3 years was 34% for the DAC-7 arm and 31% for the DA-7 arm (P ¼ NS). The LFS rate was higher for the DAC-7 group compared with that of the DA-7 (43 vs 34%); however, the difference did not reach statistical significance (Figure 2) . After censoring the data at the time of alloHSCT, the LFS rates equaled 43 vs 37%, respectively. The median time to relapse has not been reached in the DAC-7 arm and equaled 689 (25-922) in the DA-7 arm. 
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The subgroup analysis revealed a trend toward higher probability of LFS for patients receiving the DAC-7 treatment compared with the DA-7 therapy in patients aged 440 years (44 vs 28%, P ¼ 0.05) (Figure 3 ) (updated analysis performed on 10th December 2003 confirmed the difference: 32 vs 18% at four years, P ¼ 0.01). In this subgroup, 84% of patients in the DAC-7 arm and 82% in the DA-7 arm completed consolidation treatment.
Proportion of patients given auto-HSCT was 13% for DAC-7 and 14% for DA-7 and allo-HSCT 6 and 5%, respectively. After censoring the data at the time of alloHSCT, the LFS rates equaled 44% for DAC-7 vs 37% for DA-7 (P ¼ 0.08).
There was a trend for better outcome in patients with unfavorable cytogenetic features assigned to the DAC-7 arm compared with that of the DA-7 arm (LFS rate 37 vs 21%, P ¼ 0.14). No difference with regard to long-term outcome between both study arms was found in an intermediate and favorable cytogenetic risk groups as well as among patients with AML preceded by myelodysplasia (Table 3) .
Discussion
In most of the randomized trials on AML performed within the last two decades, DNR 45 mg/m 2 for 3 days þ AraC 100 mg/m 2 for 7 days was chosen as a standard remission induction regimen, to which other treatment modalities were compared. 25, 26 There are, however, cumulative data suggesting that DAC-7 vs DA-7 for induction in AML J Holowiecki et al the use of more intensive regimen may result in increased CR rate and/or improved long-term outcome. 4, 6, 7, 27, 28 The approaches to intensify induction therapy included increasing the dose of DNR, introduction of an alternative anthracycline, addition of a third agent and escalation of the dose or time of AraC administration. A comparison based on sequential studies by the SWOG and the ECOG (Eastern Cooperative Oncology Group) showed a better response rate for patients receiving DNR 60-70 mg/m 2 compared to DNR 45 mg/m 2 . 29 On the other hand, the outcome of patients treated ANC, all neutrophil count; PLT, platelets; Lym, lymphocytes; NS, nonsignificant.
Comparison of hematological toxicity and peripheral blood recovery with regard to only patients who achieved CR after a single induction course.
Table 5
Supportive treatment during the induction treatment Comparison includes all (one, two or three) induction courses during the study period.
Figure 2
Kaplan-Meier estimates for the probability of LFS in two study groups (within parenthesis -95% confidence intervals). Tick marks indicate patients alive.
Figure 3
Kaplan-Meier estimates for the probability of LFS in patients aged 440 years treated within two randomization arms (within parenthesis -95% confidence intervals). Tick marks indicate patients alive.
DAC-7 vs DA-7 for induction in AML J Holowiecki et al with DNR at the higher doses was comparable with that obtained using other agents like idarubicin, mitoxantrone, aclarubicin or amsacrine. 4, 7, 30, 31 For this reason, we used DNR at dose of 60 mg/m 2 as a reference treatment. The optimal dose of AraC in induction has not been defined so far. There is evidence that the increased dose may be associated with a longer LFS; however, no advantage in terms of CR rate was demonstrated. 27, 29 A tendency for improved survival in patients aged o60 years was found for AraC 200 mg compared with AraC 100 mg. 25 A little advantage of the AraC administered in increased dose on outcome was a consequence of increased toxicity, which is a major limitation for intensification of induction treatment. 9 In our study, we hypothesized that this problem could be partially omitted by the introduction of a purine analogue -2-CdA.
Purine analogues (FA and 2-CdA) have been extensively used in the therapy of lymphoprolipherative disorders. 32, 33 However, preclinical and clinical studies showed that these agents are also cytotoxic to the cells originating from myeloid lineage. 9 FA likewise 2-CdA was demonstrated in pharmacological studies to increase intracellular concentration of AraCTP, which is more pronounced in AML blasts than in normal progenitors. [10] [11] [12] In addition, 2-CdA show direct antimetabolic activity and provides an additional antileukemic mechanism by inducing apoptosis as a consequence of mitochondrial injury. 13, 34, 35 First reports on 2-CdA administrations in myeloid leukemia come from pediatrics. In 1992, it was demonstrated that monotherapy with 2-CdA at a dose of 8.9 mg/m 2 /day (continuous 120 h infusion) resulted in 47% CR and 12% PR rate in refractory and relapsed AML in children. 36 After 2 years, a 27% CR and a 32% PR was reported in children with AML treated de novo using the same doses of 2-CdA. 37 Combination regimens including FA, AraC and G-CSF (FLAG), the same drugs with mitoxantrone (FLANG) or 2-CdA, AraC and G-CSF (CLAG) have a documented effect on CR rates in patients with refractory leukemia [14] [15] [16] and newly diagnosed AML.
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In our study, we demonstrate that the addition of 2-CdA to DNR/AraC is not associated with increased nonhematological toxicity. Concerning the hematological toxicity, a more profound granulocytopenia and lymphopenia was observed in the DAC-7 arm, but the hematological recovery was not prolonged and the incidence of severe infections was similar in both arms. The EM was also comparable in both groups under study, suggesting that adjunct of 2-CdA to DNR and AraC does not increase the entire toxicity.
The rate of CR achieved after the first induction course was significantly higher in patients receiving DAC-7 compared with those treated with DA-7 and equaled 63.5%. This result seems to be higher also when compared with other regimens described in the previously published studies. 4, 32 In the CALGB study, 31% of patients achieving CR required two courses of DNR/ AraC induction treatment, which corresponds well with the respective value of 32% in the DA-7 arm of the current study. 38 In contrast, only 12% of CR patients required two induction courses in the DAC-7 arm. High efficacy of a single DAC-7 course together with no additional toxicity proves that addition of 2-CdA increases a selective antileukemic potency of DNR/ AraC combination. The overall CR rate was similar in both study cohorts and corresponded well with those reported by other investigators within the last decade. 1, 2, 5, 27 It must be stressed, however, that from the ethical reasons both randomization arms received 2-CdA-containing regimen (CLAG) as a second-or third-line of induction treatment. 16 It is remarkable that 12/23 (46%) of primarily resistant patients in DA-7 arm and only 1/11 (9%) of those in DAC-7 arm responded to CLAG therapy. It is reasonable therefore to use different reinduction for patients resistant to DAC-7, which may raise the final CR rate over 72%. As the higher AraC dose was not effective, the use of idarubicine or mitoxantrone and addition of etoposide should be considered.
It is of clinical importance to identify factors predictive for high response to DAC-7. So far, it was possible to prove that a significantly higher overall CR rate was obtained in patients receiving DAC-7 vs DA-7, who had at diagnosis a very high white blood cell count, exceeding 100 Â 10 9 /l. Although it is difficult to explain whether a better efficacy of 2-CdA-containing regimen in patients with bigger tumor mass is due to a higher proliferative activity or other features of leukemia, this finding is important for optimal use of the DAC-7 schedule.
Since the time to achieve CR is a well-recognized prognostic factor for long-term outcome, 39, 40 we could expect that the probability of LFS in DAC-7 arm would be higher compared with DA-7 arm. So far, the difference in favor of DAC-7 treatment is not statistically significant. The heterogeneity of the postconsolidation treatment, including various transplant modalities and maintenance therapy, makes the evaluation of longterm outcomes difficult. It seems that in older patients (440 years) as well as in those with unfavorable cytogenetics the advantage of DAC-7 vs DA-7 may be more pronounced. This observation cannot be confirmed for patients from favorable and intermediate cytogentic risk groups, so far. The effect of the addition of 2-CdA on outcome is similar for patients with and without morphological features of preceding myelodysplasia. The DAC-7 protocol is potentially advantageous for patients eligible for bone marrow transplantation. A significantly higher proportion of patients achieving CR after only one remission induction cycle may earlier proceed to bone marrow transplantation (BMT). The short time interval between diagnosis and transplantation was demonstrated to be an independent factor associated with longer survival in adults in the first CR of AML 41 and with better EFS in children. 42 The DAC-7 program providing a shortened treatment before transplantation may therefore indirectly contribute to improved survival. Such a program does not need to include a toxic, costly and time-consuming highdose AraC consolidation, which has no beneficial impact on survival in patients undergoing allogeneic BMT in the first remission. 43 A shortened program consisting of one DAC-7 and a second similar consolidation treatment administered during the time of preparation for BMT is planned as an option of the next PALG study.
Although pharmacoeconomic analysis was not the scope of this study, we analyzed supportive treatment, which is the major component that influences the cost of the therapy. We found no difference concerning consumption of blood products, cytokines or i.v. antibiotics. Moreover, the time of hospital stay during the whole induction treatment was shorter by 7 days in favor of DAC-7 arm. This was another consequence of advantage of the DAC-7 regimen resulting from higher CR rate achieved after a single course of induction in this group of patients.
We conclude that DAC-7 is a well-tolerated, feasible and effective induction regimen for adult AML. Shorter hospital stay when compared with standard induction therapy makes DAC-7 a cost-effective therapeutic option. This treatment modality should be considered specially for patients with a high tumor burden as well as for those with adverse prognostic factors. Extended trials are necessary to further explore how to make use of the higher antileukemic potency of DAC-7, which when compared to standard treatment results in 17% more patients achieving CR after only one cycle.
